Real data o viral hepatitis C therapy in the Czech Republic
Authors:
Libuše Husová
Authors‘ workplace:
Centrum kardiovaskulární a transplantační chirurgie, Brno
Published in:
Vnitř Lék 2016; 62(Suppl2): 6-9
Category:
Original Contributions
Overview
We reported the first real data about efficacy of interferon-free therapy of chronic hepatitis C in the Czech Republic. Patients were treated with combined therapy of paritaprevir/ritonavir + ombitasvir + dasabuvir with or without ribavirin. There were 109 patients, predominantly men – 62 (57 %), most of them infected by genotype 1b – 101 patients (93 %), minority infected by genotypes 1a (6/109, 5 %) and 4 (2/109, 2 %). Both treatment-naive (43/109, 39 %), and treatment-experienced patients (66/109, 61 %) were treated. Sustained virological response 12 weeks after therapy termination (SVR12) was 100 %, with exclusion of patients with other reason than virological treatment failure.
Key words:
dasabuvir – chronic hepatitis C – ombitasvir – paritaprevir/rinonavir – ribavirin
Sources
1. [European Association for the Study of Liver]. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61(2): 373–395.
2. [European Association for the Study of Liver]. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63(1): 199–236.
3. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné z WWW:
4. Urbánek P, Husa P, Šperl J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Klin Mikrobiol Inf Lek 2015; 21(3): 83–98.
5. Urbánek P. Exviera, Viekirax. Gastroent Hepatol 2015; 69(1): 75–80.
6. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1594–1603.
7. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370(21): 1983–1992.
8. Wyles DL, Sulkowski MS, Eron JJ et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology 2014; 60(Suppl 1): 1136A. Conference Report: <http://www.natap.org/2014/AASLD/AASLD_28.htm>.
9. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1604–1614.
10. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147(2): 359–365.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2016 Issue Suppl2
Most read in this issue
- Late complications of liver cirrhosis – management of gastrointestinal bleeding in the presence of portal hypertension
- Extrahepatic manifestations of HCV infection
- Real data o viral hepatitis C therapy in the Czech Republic